source
- Eli Lilly ends partnership with Foghorn Therapeutics, prompting 40% staff cut at biotechEli Lilly announced it is withdrawing from its collaboration with Foghorn Therapeutics on a synthetic lethality drug program. Following the pullback, Foghorn said it will cut roughly 40% of its wo…
- US government unveils AI-driven SURPASS program to accelerate clinical trialsThe U.S. Department of Health and Human Services announced that the Advanced Research Projects Agency for Health (ARPA-H) is launching four new initiatives aimed at modernizing clinical trial desig…